CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two ...

Core Insights - Jazz Pharmaceuticals announced improved outcomes for adults with narcolepsy or idiopathic hypersomnia treated with Xywav, as demonstrated in the Phase 4 DUET study [1][2] - The company is committed to addressing neurological disorders with limited treatment options, emphasizing the importance of ongoing data generation for Xywav and Epidiolex [3] Xywav Treatment Insights - The Phase 4 DUET trial showed statistically significant improvements in Epworth Sleepiness Scale (ESS) scores, reduced sleep stage shifts, increased deep sleep, and fewer awakenings in adults with narcolepsy treated with Xywav [2] - In adults with idiopathic hypersomnia, Xywav treatment also resulted in improvements in ESS and Idiopathic Hypersomnia Severity Scale scores [2] - Patient-reported data indicated that Xywav treatment was associated with improvements in daytime symptoms and cognitive complaints among adults with narcolepsy or idiopathic hypersomnia [2] Epidiolex Treatment Insights - A novel analysis of real-world Epidiolex treatment patterns revealed a nearly 70% (69.9%) probability of persistence at one year among new patients, highlighting the importance of dose optimization [5] - The analysis indicated that 52% of patients were taking dosages greater than 15 mg/kg/day at 12 months, with those on average dosages greater than 20 mg/kg/day having the lowest likelihood of discontinuation [5] Upcoming Presentations - Jazz Pharmaceuticals will present seven abstracts at the 2025 AAN Annual Meeting, focusing on the effectiveness and safety of Xywav and real-world data on Epidiolex [1][4]